Analysts have been eager to weigh in on the Healthcare sector with new ratings on Mersana Therapeutics (MRSN – Research Report) and Crispr Therapeutics AG (CRSP – Research Report).
Mersana Therapeutics (MRSN)
In a report released yesterday, Kaveri Pohlman from BTIG maintained a Hold rating on Mersana Therapeutics. The company’s shares closed last Tuesday at $1.19, close to its 52-week low of $0.80.
According to TipRanks.com, Pohlman ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Mersana Therapeutics with a $1.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Crispr Therapeutics AG (CRSP)
In a report issued on October 27, Gena Wang from Barclays maintained a Buy rating on Crispr Therapeutics AG, with a price target of $64.00. The company’s shares closed last Monday at $38.93, close to its 52-week low of $37.55.
According to TipRanks.com, Wang is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $84.14 average price target, an 116.0% upside from current levels. In a report issued on October 18, Mizuho Securities also maintained a Buy rating on the stock with a $82.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MRSN:
- Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023
- Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056
- Centessa adds April Dovholuk, Ellie Im to senior leadership team
- Mersana Therapeutics appoints Martin Huber as CEO
- Mersana Therapeutics Announces Changes in Leadership
